

December 01, 2020

To,
SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589

Dear Sir,

**Sub: Glenmark Pharmaceuticals receives ANDA tentative approval for Axitinib Tablets,
1 mg and 5 mg**

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited



Harish Kuber
Company Secretary & Compliance Officer

Encl: as above

Press Release

For Immediate Release

Glenmark Pharmaceuticals receives ANDA tentative approval for Axitinib Tablets, 1 mg and 5 mg

Mumbai, India, December 1, 2020: Glenmark Pharmaceuticals Inc., USA (Glenmark) has received tentative approval by the United States Food & Drug Administration (U.S. FDA) for Axitinib Tablets, 1 mg and 5 mg, the generic version of Inlyta®¹ Tablets, 1 mg and 5 mg, of PF Prism C.V.

According to IQVIA™ sales data for the 12 month period ending October 2020, the Inlyta® Tablets, 1 mg and 5 mg market² achieved annual sales of approximately \$518.8 million*.

Glenmark's current portfolio consists of 166 products authorized for distribution in the U.S. marketplace and 45 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

—End—

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019). For more information, visit www.glenmarkpharma.com

For more information:

Glenmark Media Contact

Udaykumar Murthy
Senior Manager, Corporate Communications
+91 9960377617
corpcomm@glenmarkpharma.com

¹All brand names and trademarks are the property of their respective owners.

²Market includes brand and all available therapeutic equivalents

*IQVIA™ National Sales Perspectives: Retail & Non-Retail, October 2020